[go: up one dir, main page]

MX2015009045A - Compositions and methods for treating severe pain. - Google Patents

Compositions and methods for treating severe pain.

Info

Publication number
MX2015009045A
MX2015009045A MX2015009045A MX2015009045A MX2015009045A MX 2015009045 A MX2015009045 A MX 2015009045A MX 2015009045 A MX2015009045 A MX 2015009045A MX 2015009045 A MX2015009045 A MX 2015009045A MX 2015009045 A MX2015009045 A MX 2015009045A
Authority
MX
Mexico
Prior art keywords
methods
compositions
severe pain
treating severe
pharmaceutical compositions
Prior art date
Application number
MX2015009045A
Other languages
Spanish (es)
Inventor
John Brew
Robin Mark Bannister
George William Schlich
Original Assignee
Infirst Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infirst Healthcare Ltd filed Critical Infirst Healthcare Ltd
Publication of MX2015009045A publication Critical patent/MX2015009045A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente especificación revela composiciones farmacéuticas, métodos de preparación de dichas composiciones farmacéuticas, y métodos y usos de tratamiento de una inflamación crónica y/o una enfermedad inflamatoria en un individuo utilizando dichas composiciones farmacéuticas.The present specification discloses pharmaceutical compositions, methods of preparation of said pharmaceutical compositions, and methods and uses of treatment of a chronic inflammation and / or an inflammatory disease in an individual using said pharmaceutical compositions.

MX2015009045A 2013-01-14 2014-01-14 Compositions and methods for treating severe pain. MX2015009045A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361752356P 2013-01-14 2013-01-14
PCT/EP2014/050628 WO2014108569A1 (en) 2013-01-14 2014-01-14 Compositions and methods for treating severe pain

Publications (1)

Publication Number Publication Date
MX2015009045A true MX2015009045A (en) 2015-12-17

Family

ID=50064547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009045A MX2015009045A (en) 2013-01-14 2014-01-14 Compositions and methods for treating severe pain.

Country Status (14)

Country Link
EP (1) EP2943183A1 (en)
JP (1) JP6474732B2 (en)
KR (1) KR20150129665A (en)
CN (1) CN104968330A (en)
AU (1) AU2014204739B2 (en)
BR (1) BR112015015864B1 (en)
CA (1) CA2897874A1 (en)
HK (1) HK1217650A1 (en)
IL (1) IL239921A0 (en)
MX (1) MX2015009045A (en)
RU (1) RU2677346C2 (en)
SG (1) SG11201505245XA (en)
WO (1) WO2014108569A1 (en)
ZA (1) ZA201505005B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11896037B2 (en) * 2016-08-03 2024-02-13 Temple University-Of The Commonwealth System Of Higher Education Microencapsulation of active agents
JP7027786B2 (en) * 2017-10-12 2022-03-02 ライオン株式会社 Oral treatment for myofascial pain
KR20240021751A (en) 2021-03-27 2024-02-19 티알엑스 바이오사이언시스 리미티드 Composition with improved bioavailability of therapeutic agent
CN116660550B (en) * 2023-06-19 2024-08-13 南通大学 Method for alleviating pain by using a DGAT2 inhibitor PF-06424439

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
WO1999006044A1 (en) * 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
DK0999826T3 (en) * 1997-07-29 2004-07-26 Upjohn Co Self-emulsifying formulation for lipophilic compounds
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MXPA01011343A (en) * 1999-05-07 2002-06-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same.
US8663692B1 (en) * 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
DE60005819T2 (en) * 1999-06-14 2004-05-06 Cosmo S.P.A. TASTE-MASKED ORAL PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED DELIVERY
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
JP2002284705A (en) * 2001-01-19 2002-10-03 Shiseido Co Ltd Torpent
GB0402679D0 (en) * 2004-02-06 2004-03-10 Novartis Ag Organic compounds
KR20070084531A (en) * 2004-11-24 2007-08-24 머크 앤드 캄파니 인코포레이티드 Liquid and semisolid pharmaceutical forms for oral administration of substituted amides
CN101189029A (en) * 2005-04-28 2008-05-28 盖伦尼卡技术股份公司 Pharmaceutical dosage forms containing a lipid phase
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
EP2310371B1 (en) 2008-05-26 2013-05-15 Genfit Ppar agonist compounds and preparation and uses thereof for treating diabetes and/or dyslipidemia
CN102048680B (en) * 2009-11-11 2013-05-01 河北奥星集团药业有限公司 Enteric sustained-release preparation containing zaltoprofen and preparation method thereof
AU2012213217B2 (en) * 2011-02-04 2017-04-20 Infirst Healthcare Limited Compositions and methods for treating cardiovascular diseases
CN102579350B (en) * 2012-03-02 2013-04-24 海南灵康制药有限公司 Pidotimod liposome solid preparation

Also Published As

Publication number Publication date
SG11201505245XA (en) 2015-08-28
BR112015015864B1 (en) 2022-08-23
JP2016504401A (en) 2016-02-12
EP2943183A1 (en) 2015-11-18
CA2897874A1 (en) 2014-07-17
JP6474732B2 (en) 2019-02-27
CN104968330A (en) 2015-10-07
WO2014108569A1 (en) 2014-07-17
AU2014204739A1 (en) 2015-07-16
RU2015134136A (en) 2017-02-20
BR112015015864A8 (en) 2018-01-16
IL239921A0 (en) 2015-08-31
AU2014204739B2 (en) 2016-08-11
KR20150129665A (en) 2015-11-20
HK1217650A1 (en) 2017-01-20
RU2677346C2 (en) 2019-01-16
ZA201505005B (en) 2016-10-26
BR112015015864A2 (en) 2017-07-11

Similar Documents

Publication Publication Date Title
MX2015009045A (en) Compositions and methods for treating severe pain.
MX366317B (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
MX377340B (en) SOLID SOLUTION COMPOSITIONS AND USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES.
IL285474A (en) Anti-pdl1 antibody aqueous pharmaceutical formulations for use in treating infection, cancer, and inflammatory diseases
EP3052476A4 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
MX346224B (en) Compostions and methods for treating chronic inflammation and inflammatory diseases.
IL253066A0 (en) Cannabis-based extracts and formulations for topical administration for use in the treatment of skin diseases
MX2020009780A (en) Autotaxin inhibitor compounds.
MX375752B (en) BRUTON'S TYROSINE KINASE INHIBITORS.
HUE046671T2 (en) A pharmaceutical composition containing glutarimide derivatives and its use in the treatment of eosinophilic diseases
EA201690039A1 (en) RORC2 INHIBITORS AND METHODS OF THEIR APPLICATION
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
LT3168214T (en) MODIFIED 2-THYXO-IMIDAZOLIDIN-4-ONES AND THEIR SPIRO ANALOGES, ACTIVE ANTICIPAL COMPOSITION, PHARMACEUTICAL COMPOSITION, MEDICAL PREPARATION, PROSTATE CANCER TREATMENT
MX375318B (en) DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLORINE KYNURENINE.
UA118474C2 (en) (S) -PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTED SALTS FOR MEDICINAL USE
LT3229790T (en) COMPOSITIONS INCLUDING MEDIUM-CHAIN TRIGLYCERIDES FOR USE IN THE TREATMENT OF EPILEPSIA
MX2016011025A (en) GRAPIPRANT COMPOSITIONS AND METHODS TO USE THE SAME.
MX381429B (en) Trichostatin A (TSA) for use in the treatment of cancer.
UA116499C2 (en) (R) -PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTED SALTS FOR MEDICINAL USE
AR130700A2 (en) GRAPIPRANT COMPOSITIONS AND METHODS OF USE
PH12020500472A1 (en) Autotaxin inhibitor compounds
LT3052476T (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
TH1401007652A (en) Aminotriazolopyridines for use in the treatment of inflammation and its pharmaceutical composition
TH1401006421A (en) Compounds for use in the manufacture of drugs for the treatment of steroid-responsive skin diseases.
IN2013MU03429A (en)